Pillstats
Rx only · Tablet, Film Coated · Oral

Ertugliflozin

Brands: Steglatro · Ertugliflozin Pidolate

1 ACTIVE SUPPLIER — US
openFDA · updated weekly
US2 NDCs
1 active makers
UKComing
soon
CAComing
soon
AUComing
soon
EUComing
soon
ATCA10BK04
RxCUI (US)1992672
US makers1 labelers
Packages9
DEA / ScheduleNone

US acquisition costNADAC · per unit

Average across 4 priced NDCs. A benchmark of pharmacy acquisition cost — not a retail quote.

$3.29$6.58$9.86$13.15Dec 2025Apr 2026Jul 2026
$11.437
Latest avg · Jul 22, 2026
+0%
Since Dec 17, 2025
1
Active US suppliers
100%
Top-2 supplier share*

Medicaid dispensing volumeSDUD · per quarter

Prescriptions dispensed under Medicaid (fee-for-service + managed care), summed nationally. The closest free proxy to sales volume — Medicaid only, not all-payer.

29K58K87K116K2025 Q12025 Q22025 Q32025 Q42026 Q1
67K
Rx · 2026 Q1
2.6M
Units dispensed
-34%
Rx vs. year ago
5
Quarters · since 2025 Q1

Who makes it1 active · 0 exited

US labelers as registered with FDA. Repackagers relabel another company's product; share* is of listed packages, not sales.

LabelerTypePackagesStatus
Merck Sharp & Dohme LLC.unknown9SUPPLYING

Regulatory & supply eventsFDA · US

Shortages, recalls, and registration changes attached to this drug concept.

  • Mar 15, 2021
    RECALLRecall (Class II): Steglatro (ertugliflozin) tablets 15 mg 30 Tablets Rx only NDC 0006-5364-03 Manuf. for: Merck Sharp & Dohme Corp., a su…

    CGMP Deviations: Intermittent exposure to temperature excursion during storage. — Recalling firm: Cardinal Health Inc. — FL, GA, SC